Amgen (AMGN) last issued guidance on February 3, 2026 for fiscal year 2026. The company guided earnings per share in the range of $21.60 - $23.00, compared to a consensus EPS estimate of $22.02. Amgen also guided revenue in the range of $37.00B - $38.40B for the period.
Compared to prior guidance, Amgen raised its revenue forecast from a prior range of $35.80B - $36.60B.
Amgen has issued 15 guidance updates between August 4, 2022 and February 3, 2026. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
Review all historical guidance issued by Amgen, including EPS and revenue forecasts across quarterly and annual periods.
The most recent guidance for Amgen (AMGN) was reported on February 3, 2026 for the fiscal year 2026. The company provided earnings per share guidance in the range of $21.60 to $23.00, compared to the estimated EPS of $22.02. Additionally, Amgen forecasted revenue between $37.00B and $38.40B for the period.
Amgen (AMGN) guided EPS in the range of $21.60 to $23.00 for the fiscal year 2026. The consensus analyst EPS estimate is $22.02.
Amgen (AMGN) guided revenue in the range of $37.00B to $38.40B for the fiscal year 2026.
Amgen (AMGN) raised its revenue guidance from a prior range of $35.80B - $36.60B to $37.00B - $38.40B for the fiscal year 2026.
Amgen (AMGN) last issued guidance on February 3, 2026 for the fiscal year 2026.